<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02202980</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-337-1468</org_study_id>
    <nct_id>NCT02202980</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection</brief_title>
  <official_title>A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>New Zealand: Medsafe</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the antiviral efficacy, safety, and tolerability of combination
      therapy with oral regimens for the treatment of chronic hepatitis C virus (HCV) infection.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</measure>
    <time_frame>Posttreatment Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR12 is defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of any adverse events leading to permanent discontinuation of study drug(s)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</measure>
    <time_frame>Posttreatment Weeks 4 and 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR4 and SVR24 are defined as HCV RNA &lt; LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with on treatment virologic failure and relapse</measure>
    <time_frame>Up to Posttreatment Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>On treatment virologic failure is defined as:
HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ, while on treatment,
&gt; 1 log10 IU/mL increase in HCV RNA from nadir while on treatment,
HCV RNA persistently ≥ LLOQ through 8 weeks of treatment (ie nonresponse)
Relapse is defined as:
HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA &lt; LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with sustained virologic response (ie, HCV RNA &lt; LLOQ) while on treatment</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Actual">273</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>LDV/SOF+RBV 24 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who previously received ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) plus ribavirin (RBV) for ≥ 12 weeks without achieving SVR12 will receive LDV/SOF+RBV for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF+RBV 12 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who previously received a sofosbuvir-based regimen without achieving SVR12 will receive LDV/SOF+RBV for 12 weeks (excluding participants who previously received LDV/SOF+RBV for ≥ 12 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF GT2 12 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 2 (GT2) HCV infection will receive LDV/SOF FDC for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF GT2 8 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 2 HCV infection will receive LDV/SOF FDC for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF GT1 or GT2 12 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 1 (GT1) or genotype 2 (GT2) HCV infection and extrahepatic manifestations of chronic HCV infection will receive LDV/SOF FDC for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF+RBV GT3 12 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 3 (GT3) HCV infection and extrahepatic manifestations of chronic HCV infection will receive LDV/SOF FDC plus RBV for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9857 100 mg + SOF/GS-5816 TN GT1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naive (TN) participants with genotype 1 HCV infection without cirrhosis will receive GS-9857 100 mg on Day 1 followed by GS-9857 100 mg plus SOF/GS-5816 for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9857+SOF/GS-5816 TN GT1 4 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naive participants with genotype 1 HCV infection without cirrhosis will receive up to 300 mg of GS-9857 plus SOF/GS-5816 for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9857+SOF/GS-5816 TN GT1 6 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naive participants with genotype 1 HCV infection with cirrhosis will receive up to 300 mg of GS-9857 plus SOF/GS-5816 for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9857+SOF/GS-5816 TN GT3 6 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naive participants with genotype 3 (GT3) HCV infection with cirrhosis will receive up to 300 mg of GS-9857 plus SOF/GS-5816 for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9857+SOF/GS-5816 GT1 TE 6 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-experienced (TE) participants with genotype 1 HCV infection with cirrhosis will receive up to 300 mg of GS-9857 plus SOF/GS-5816 for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9857+SOF/GS-5816 TE GT3 6 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-experienced participants with genotype 3 HCV infection with cirrhosis will receive up to 300 mg of GS-9857 plus SOF/GS-5816 for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9857+SOF/GS-5816 TE PI GT1 6 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-experienced participants with genotype 1 HCV infection with or without cirrhosis who were previously treated with non-structural protein (NS)3/4A protease inhibitor (PI) will receive up to 300 mg of GS-9857 plus SOF/GS-5816 for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9857+SOF/GS-5816 TE DAA GT1 6 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-experienced participants with genotype 1 HCV infection with or without cirrhosis who were previously treated with direct acting antivirals (DAA) will receive up to 300 mg of GS-9857 plus SOF/GS-5816 for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9857+SOF/GS-5816 TE DAA GT3 6 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-experienced participants with genotype 3 HCV infection with or without cirrhosis who were previously treated with direct acting antivirals (DAA) will receive up to 300 mg of GS-9857 plus SOF/GS-5816 for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDV/SOF</intervention_name>
    <description>Ledipasvir 90 mg/sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily</description>
    <arm_group_label>LDV/SOF+RBV 24 wk</arm_group_label>
    <arm_group_label>LDV/SOF+RBV 12 wk</arm_group_label>
    <arm_group_label>LDV/SOF GT2 12 wk</arm_group_label>
    <arm_group_label>LDV/SOF GT2 8 wk</arm_group_label>
    <arm_group_label>LDV/SOF GT1 or GT2 12 wk</arm_group_label>
    <arm_group_label>LDV/SOF+RBV GT3 12 wk</arm_group_label>
    <other_name>GS-7977</other_name>
    <other_name>PSI-7977</other_name>
    <other_name>GS-5885</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBV</intervention_name>
    <description>Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)</description>
    <arm_group_label>LDV/SOF+RBV 24 wk</arm_group_label>
    <arm_group_label>LDV/SOF+RBV 12 wk</arm_group_label>
    <arm_group_label>LDV/SOF+RBV GT3 12 wk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9857</intervention_name>
    <description>GS-9857 tablets administered orally once daily with food</description>
    <arm_group_label>GS-9857 100 mg + SOF/GS-5816 TN GT1</arm_group_label>
    <arm_group_label>GS-9857+SOF/GS-5816 TN GT1 4 wk</arm_group_label>
    <arm_group_label>GS-9857+SOF/GS-5816 TN GT1 6 wk</arm_group_label>
    <arm_group_label>GS-9857+SOF/GS-5816 TN GT3 6 wk</arm_group_label>
    <arm_group_label>GS-9857+SOF/GS-5816 GT1 TE 6 wk</arm_group_label>
    <arm_group_label>GS-9857+SOF/GS-5816 TE GT3 6 wk</arm_group_label>
    <arm_group_label>GS-9857+SOF/GS-5816 TE PI GT1 6 wk</arm_group_label>
    <arm_group_label>GS-9857+SOF/GS-5816 TE DAA GT1 6 wk</arm_group_label>
    <arm_group_label>GS-9857+SOF/GS-5816 TE DAA GT3 6 wk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF/GS-5816</intervention_name>
    <description>Sofosbuvir (SOF) 400 mg/GS-5816 100 mg fixed-dose combination (FDC) tablets administered orally once daily</description>
    <arm_group_label>GS-9857 100 mg + SOF/GS-5816 TN GT1</arm_group_label>
    <arm_group_label>GS-9857+SOF/GS-5816 TN GT1 4 wk</arm_group_label>
    <arm_group_label>GS-9857+SOF/GS-5816 TN GT1 6 wk</arm_group_label>
    <arm_group_label>GS-9857+SOF/GS-5816 TN GT3 6 wk</arm_group_label>
    <arm_group_label>GS-9857+SOF/GS-5816 GT1 TE 6 wk</arm_group_label>
    <arm_group_label>GS-9857+SOF/GS-5816 TE GT3 6 wk</arm_group_label>
    <arm_group_label>GS-9857+SOF/GS-5816 TE PI GT1 6 wk</arm_group_label>
    <arm_group_label>GS-9857+SOF/GS-5816 TE DAA GT1 6 wk</arm_group_label>
    <arm_group_label>GS-9857+SOF/GS-5816 TE DAA GT3 6 wk</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  Chronic HCV infection

          -  Cirrhosis determination (liver biopsy may be required)

          -  Screening laboratory values within specified limits

          -  Males and females of childbearing potential who engage in heterosexual intercourse
             must agree to use protocol specified method(s) of contraception

          -  Specific genotype, prior medical history, or concurrent disease as required by the
             specific study group

        Exclusion Criteria:

          -  History of clinically significant illness or any other medical disorder that may
             interfere with subject treatment, assessment or compliance with the protocol

          -  Pregnant or nursing female, or male with pregnant female partner

          -  Clinical hepatic decompensation (ie, ascites, encephalopathy or variceal hemorrhage)

          -  Use of any prohibited concomitant medications
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert H Hyland, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 17, 2015</lastchanged_date>
  <firstreceived_date>July 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
